Introducing the study “Falsified medicines and the global public’s health”
David Taylor, Professor of Pharmaceutical and Public Health Policy, UCL School of Pharmacy
Geneva Pharma Forum: The Threat of False Friends Fake Medicines – Imminent Risks to Global Health to Global Health
About IFPMA
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) represents over 90 innovative pharmaceutical companies and associations around the world. Our industry’s almost three million employees discover, develop, and deliver medicines and vaccines that advance global health. Based in Geneva, IFPMA has official relations with the United Nations and contributes industry expertise to help the global health community improve the lives of people everywhere. For more information, visit ifpma.org.
Learn more
Related news and resources
Key considerations on the scope, utility and processes around updating the WHO Essential Medicines List
The WHO Essential Medicines List (EML) is an important tool in global health and supports the achievement of the UN Sustainable Development Goals. IFPMA has published perspectives from the R&D-based industry on the utility and scope of the EML. This position paper represents IFPMA's perspective as of April 2023, ahead of the publication of the revised version of the EML.
Read moreSubstandard and falsified medical products (EB152)
On 1 February 2023, IPSF submitted a statement delivered on behalf of IPSF, IAPO, and IFPMA for the WHO EB152 agenda item related to substandard and falsified medical products.
Read moreTechnology Transfer: A Collaborative Approach to Improve Global Health
The transfer of advanced technology is essential for economic development. It enables countries to accelerate the acquisition of knowledge, experience and equipment related to advanced, innovative industrial products and processes. This, in turn, builds the skills of the local workforce and creates new high-tech employment opportunities.
Read more